Fintel reports that on December 11, 2025, Bernstein initiated coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a Outperform ...

BridgeBio Pharma (BBIO) has surged 145% over the past year, reaching an all-time high of $75.10. BBIO maintains a strong ...

The average one-year price target for BridgeBio Pharma (NasdaqGS:BBIO) has been revised to $82.90 / share. This is an increase of 16.55% from the prior estimate of $71.13 dated November 7, 2025. The ...

BridgeBio Oncology Therapeutics (BBOT) targets KRAS and PI3Ka malignancies with next-generation small molecule therapeutics, ...

Chinmay Shukla: Good afternoon, everyone, and thank you for joining BridgeBio Pharma's Third Quarter 2025 Earnings Call. I'm Chinmay Shukla, Senior Vice President of Strategic Finance at BridgeBio.

Detailed price information for Bridgebio Pharma Inc (BBIO-Q) from The Globe and Mail including charting and trades.

Thomas Trimarchi, President and CFO of BridgeBio Pharma, Inc. (NASDAQ:BBIO), sold a total of 16,934 shares of common stock on November 17, 2025, in two separate transactions. The sales, executed under ...

Detailed price information for Bridgebio Pharma Inc (BBIO-Q) from The Globe and Mail including charting and trades.

Bernstein initiated coverage of BridgeBio (BBIO) with an Outperform rating and $94 price target The firm believes expectations for Attruby are ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product ...